TNF-α抑制剂在炎症性肠病治疗中的应用

摘要

TNF⁃α has been widely accepted as a therapeutic tar⁃get for inflammatory disorders including inflammatory bowel dis⁃ease. TNF⁃α inhibitors monoclonal antibodies including inflix⁃imab, adalimumab, golimumab, and certolizumabpegol had been approved by FDA for the treatment of IBD. IBD patients will bene⁃fit from a more thorough understanding of the mechanism of TNF⁃α monoclonal antibodies and the development of safe and effective strategies to IBD treatment.%TNF⁃α作为治疗包括炎症性肠病在内的炎症紊乱性疾病的治疗靶标已被广泛接受。 TNF⁃α抑制剂英夫利昔单抗、阿达木单抗、戈利木单抗以及聚乙二醇结合赛妥珠单抗均已由FDA批准用于IBD的治疗。因此，深入了解TNF⁃α单克隆抗体的作用机制以及安全有效的用于IBD的治疗将为IBD患者带来更多获益。